Wer von euch kennt den Neuen Biotech Knaller: "Esperion Therapeutics" - 500 Beiträge pro Seite

[Kolosi]

Tuesday September 5, 7:55 am Eastern Time
Press Release
SOURCE: Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. Announces Second Quarter 2000 Financial Results
ANN ARBOR, Mich., Sept. 5 /PRNewswire/ -- Esperion Therapeutics, Inc., (Nasdaq: ESPR - news), a company in the field of discovering and developing pharmaceutical products for the treatment of cardiovascular disease, today reported financial results for the second quarter ended June 30, 2000.

Esperion reported a net loss of $6.5 million for the second quarter of 2000, compared to a net loss of $2.9 million for the second quarter of 1999. The basic net loss per share was $2.95 for the three months ended June 30, 2000, compared with $1.68 for the comparable period in 1999. The pro forma net loss per share for the second quarter of 2000 was $0.36, compared to $0.31 for the second quarter of 1999. Pro forma earnings per share give effect to the conversion of all outstanding shares of convertible preferred stock from the date of issuance. Total operating expenses for the second quarter of 2000 were $6.8 million, compared with $3.0 million for the second quarter of 1999, reflecting increased spending on the research and development of our product candidates, including new product candidates discovered or in- licensed over the past year.

For the six months ended June 30, 2000, Esperion reported a net loss prior to the beneficial conversion feature of $11.2 million compared with a net loss for the six months ended June 30, 1999 of $4.3 million, respectively. The basic net loss per share was $5.35 and $2.53 for each six-month period, respectively, and the pro forma net loss per share was $0.64 and $0.47 for the same six-month periods, respectively. The net loss and per share amounts for the six months ended June 30, 2000 exclude a one-time, non-cash charge related to the beneficial conversion feature on preferred stock of $22.9 million. This charge was taken in the first quarter of 2000.

The Company did not report any revenue for the three months ended June 30, 2000 and 1999, or the six months ended June 30, 2000 and 1999. Esperion continues to focus on the discovery and development of new and innovative products for the cardiovascular disease market.

As of June 30, 2000, Esperion had $22.7 million in cash and cash equivalents, compared with $5.9 at December 31, 1999. Net cash used in operations in the first six months of 2000 was $8.9 million.

``We are pleased with the financial results for the quarter, which are in line with our own projections,`` stated Roger Newton, President and Chief Executive Officer of Esperion Therapeutics. ``Our product candidates for the treatment of atherosclerosis, which are in early stages of development are, for now, exceeding our expectations.``

``We are also quite pleased with two other developments that occurred after the quarter ended June 30, 2000,`` continued Dr. Newton. ``First, we raised total net proceeds of $50.2 million from the Initial Public Offering (IPO) in August, excluding the underwriters` overallotment option, which may be exercised within 30 days of the offering. The IPO marked an important step for funding the Company`s efforts in the development of new medicines. The net proceeds of the offering will be used for the further development and commercialization of our product candidates, payments under existing license agreements, ongoing research and development activities and general corporate and working capital purposes. Second, in August, we signed a non-binding letter of intent to acquire Talaria Therapeutics, Inc. in settlement of litigation against us and other defendants. If completed, this acquisition will provide both additional intellectual property and Phase I clinical data that should advance the development of our LUV product candidate.``

Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular disease, which is disease of the heart and the body`s blood vessels and related organs. Esperion intends to commercialize a novel class of drugs that focus on a new treatment approach called ``HDL Therapy,`` which is based on the Company`s understanding of high density lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway. The RLT pathway is responsible for removing excess cholesterol from arteries and other tissues and for its transport to the liver for elimination from the body. Esperion`s goal is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. Esperion currently has five product candidates under development for the treatment of cardiovascular disease. Esperion successfully completed an initial public offering on August 9, 2000, and is listed on the Nasdaq National Market under the symbol ``ESPR``.

Statements included in this press release that are not historical in nature are ``forward-looking statements`` within the meaning of the ``safe harbor`` provisions of the Private Securities Litigation Reform Act of 1995. These include statements regarding the progress of our products in development and the potential acquisition of Talaria Therapeutics, Inc. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties that may cause actual results, performance or achievements, or industry results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. These include, for example, risks associated with the development of our product candidates, including regulatory approval, market acceptance, the Company`s dependence on clinical research organizations, license arrangements and other strategic relationships, the Company`s dependence on patents and proprietary rights, the Company`s procurement, maintenance, enforcement and defense of its patents and proprietary rights, risks related to manufacturing, and the ability to consummate the acquisition of Talaria. These risks and uncertainties and other risks and factors are more fully described in the Company`s Form S-1 Registration Statement.


Web site: http://www.esperion.com
Esperion Therapeutics, Inc. Announces the Exercise of Over-Allotment Option For the Purchase of 900,000 Shares of Common Stock
ANN ARBOR, Mich., Sept. 8 /PRNewswire/ -- Esperion Therapeutics, Inc., (Nasdaq: ESPR - news) today announced the sale of 900,000 shares of common stock at a price of $9.00 per share pursuant to the exercise of the underwriters` over-allotment option.

The over-allotment option was granted in connection with Esperion`s Initial Public Offering on August 9, 2000 of 6,000,000 shares of common stock, all of which were sold by the Company. With the exercise of the underwriters` over-allotment option, total proceeds to Esperion from the offering are approximately $57.8 million, after deducting the underwriting discount. The shares were offered by an underwriting group led by FleetBoston Robertson Stephens Inc., Chase H&Q and U.S. Bancorp Piper Jaffray Inc.

``We now have over $75.0 million in cash, which will be used for the further development and commercialization of our product candidates, payments under existing license agreements, ongoing research and development activities and general corporate and working capital purposes,`` stated Roger Newton, President and Chief Executive Officer of Esperion Therapeutics. ``Our current portfolio of product candidates provides us with a unique opportunity to develop new medicines for HDL Therapy to advance the treatment of cardiovascular and metabolic diseases.``

Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular disease, which is disease of the heart and the body`s blood vessels and related organs. Esperion intends to commercialize a novel class of drugs that focus on a new treatment approach called ``HDL Therapy,`` which is based on the Company`s understanding of high density lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway. The RLT pathway is responsible for removing excess cholesterol from arteries and other tissues and for its transport to the liver for elimination from the body. Esperion`s goal is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. Esperion currently has five product candidates under development for the treatment of cardiovascular disease. Esperion successfully completed an initial public offering on August 9, 2000, and is listed on the Nasdaq National Market under the symbol ``ESPR.``

Statements included in this press release that are not historical in nature are ``forward-looking statements`` within the meaning of the ``safe harbor`` provisions of the Private Securities Litigation Reform Act of 1995. These include statements regarding the progress of Esperion`s products in development. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties that may cause actual results, performance or achievements, or industry results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. These include, for example, risks associated with the development of Esperion`s product candidates, including regulatory approval, market acceptance, the Company`s dependence on clinical research organizations, license arrangements and other strategic relationships, the Company`s dependence on patents and proprietary rights, the Company`s procurement, maintenance, enforcement and defense of its patents and proprietary rights, and risks related to manufacturing. These risks and uncertainties and other risks and factors are more fully described in the Company`s Form S-1 Registration Statement.

SOURCE: Esperion Therapeutics, Inc.

[Kolosi]

Esperion ist in Deutschland noch ein unendtecker Wert mit viel Potenzial!
Im Nasdaq werden über 1 Millionen Aktien gehandelt!

[Kolosi]

Esperion Explodiert!

[habkeingeld]

Hi Kolosi
willste uns verarschen ?? 1mio Aktien im Jahr oder was meinst du damit!!!?

[Kolosi]

Ich will euch nicht verrarschen das ist ein Knaller!